

Sanaplas GmbH

Product | Fact Sheet

ACS

Allogeneic Curative Serum



Company
Sanaplas GmbH

Product
ACS – Eye Drops

Contact

Dr. Klaus Menken
Klaus.Menken@sanaplas.com | ☎ +49 176 503 303 49

FOLLOW US



Business Case

Two parallel utilization models:

1. acute care of patients with sicca syndrome
2. Prophylactic post-laser therapy

Market	Sicca (EU)	Laser (EU)
TAM	80.000.000	757.000
SAM	16.000.000	757.000
SOM	6% 960.000	50% 378.500
Peak Sales	495 M €	35 M €
ROI	> 20%	

Estimated Net Result next 20y (without post-laser therapy)

Development Phase (2024-2029)	- 64,3 M €
Launch - Break Even (2030 - mid 2033)	+ 64,3 M €
Profit zone (mid 2033 - 2043)	1.505,1 M €

Investment Potential

Exit	PP	Invest	Shares
I	20 M €	5,3 M € / Series A	
II	212 M €	62,7 M € / Series B	
III	546 M €		

ACS | Eye Drops

Unsatisfactory therapy for moderate and severe sicca syndrome:
painful eye inflammation, loss of eyesight



 80 million sicca patients in Europe

 16 million patients with moderate or severe symptoms

Today < no cure achievable with standard medication - only symptom relief through a combination of moisturizing and anti-inflammatory eye drops.

2 in 1 efficacy and tolerability of serum eye drops is well known, but patient individual preparation is cost-intensive and time-consuming.

Tomorrow > **2 in 1 Therapy** | Allogeneic Curative Serum (ACS)

ACS utilizes the known mechanism of action of natural serum and is the first serum-product, which can be produced as a standardized product in consistently high quality on an industrial scale; at competitive costs.

Company
Sanaplas GmbH

Product
ACS - Eye Drops

Contact

Dr. Klaus Menken
Klaus.Menken@sanaplas.com | ☎ +49 176 503 303 49

FOLLOW US



Development Status and Patent Situation

> Composition of matter patent

- Europe (EPA): granted in Q1 2024
- International: PCT-application filed in July 2022, Country selection in Oct. 2024

> Concept

Agreed on with Federal Institute for Vaccines and Biomedicines (Paul-Ehrlich-Institute, PEI)

- Consent to industrial production process
- Preclinical in vitro assays accepted
- Phase I clinical trial not required
- Green light for clinical phase II study (blinded, randomized, 20 patients)

The Study Center at the University Clinic for Ophthalmology of the Hannover Medical School is open for consultation or as clinical trial site, offering scientific and economic advantages

Next Steps | Costs

Next steps to Exit Model II - clinical phase II potentially with the MHH; in parallel further development of the production process to industrial scale

- > financial requirements in total 5,3 M €
- > amount not yet reflecting potential public funding: assumed to be up to 2 M €

Potential Participation

Scenario 1 – Share Deal

We offer a cooperation either till EXIT II or to bring the product to the market as quickly as possible. Sanaplas will provide the necessary IP and know-how. The costs for the next steps up to marketing authorization are borne by the cooperation partner.

The product is then brought to market by our partner.

In either case, a CEO will be hired, who is experienced in acquiring funding and the challenges of implementing the next steps.

Scenario 2 – Asset Deal

Sale of IP and know-how

Company
Sanaplas GmbH

Product
ACS – Eye Drops

Contact

Dr. Klaus Menken
Klaus.Menken@sanaplas.com | ☎ +49 176 503 303 49

FOLLOW US



Contact Us

Have questions or want more information? We're here to assist you. Reach out to us at your convenience; and let's explore how we can work together.

Reach Out to Us

Feel free to use the contact form below or contact us directly:

Email: Klaus.Menken@sanaplas.com

Phone: +49 176 503 303 49
We're looking forward to connecting with you.



Andrea Jochheim-Richter

Dr. Andrea Jochheim-Richter, inventor and manager of the project remains in the team supported by long-standing colleagues who are proven experts in the field.